Cedars-Sinai Lands Avon Funds for Breast Cancer MicroRNA Study | GenomeWeb

NEW YORK (GenomeWeb News) – An investigator at the Cedars-Sinai Oschin Comprehensive Cancer Institute has landed a $300,000 in funding from the Avon Foundation for Women to study blood-based biomarkers that could be used to treat and stratify breast cancer patients.

Associate Professor Dolores Di Vizio plans to use the funding to study miRNAs found in oncosomes, large bioactive lipid-enclosed vesicles that originate in tumor cells and circulate in plasma, with a focus on how they might be used to indicate tumor progression.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.